Lifetime cost-effectiveness of rosiglitazone/metformin fixed dose combination for the treatment of type 2 diabetes in Portugal

被引：0
|
作者：
Taylor, M.
Shearer, A.
Bagust, A.
Vaz, J. P.
Pereira, J.
机构：
来源：
DIABETES | 2006年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：A548 / A548
页数：1
相关论文
共 50 条
  • [21] Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview
    Jaime A. Davidson
    Lance Sloan
    Advances in Therapy, 2017, 34 : 41 - 59
  • [22] Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes
    Frias, Juan Pablo
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2019, 14 (02) : 75 - 83
  • [23] COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS ADD-ON TO METFORMIN FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Tzanetakos, C.
    Tentolouris, N.
    Kourlaba, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2015, 18 (07) : A606 - A607
  • [24] Cost-effectiveness of treatment of type 2 diabetes
    Eastman, RC
    DIABETES CARE, 1998, 21 (03) : 464 - 465
  • [25] Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US
    Tunis, Sandra L.
    Minshall, Michael E.
    Charles, Meaghan St.
    Pandya, Bhavik J.
    Baran, Robert W.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) : 3085 - 3096
  • [26] Metformin/rosiglitazone combination pill (Avandamet®) for the treatment of patients with Type 2 diabetes
    Smiley, Dawn
    Umpierrez, Guillermo
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (09) : 1353 - 1364
  • [27] Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation
    Czoski-Murray, C
    Warren, E
    Chilcott, J
    Beverley, C
    Psyllaki, MA
    Cowan, J
    HEALTH TECHNOLOGY ASSESSMENT, 2004, 8 (13) : 1 - +
  • [28] Letter to the editor in reference to article titled: Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes
    Pokharna, H.
    Kanna, B.
    DIABETES OBESITY & METABOLISM, 2007, 9 (06): : 914 - 914
  • [29] A cost-effectiveness evaluation of adding rosiglitazone versus sulphonylurea to metformin in a US obese Type 2 diabetes population.
    Beale, SJ
    Bagust, A
    Richter, A
    Thieda, P
    Perry, A
    DIABETOLOGIA, 2003, 46 : A444 - A444
  • [30] Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes
    Cai, Xiaoling
    Shi, Lizheng
    Yang, Wenjia
    Gu, Shuyan
    Chen, Yingyao
    Nie, Lin
    Ji, Linong
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 336 - 343
12345